Mielóma multiplex: vizsgálatok itt: Dánia
22 of 26 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Aalborg, Aarhus N, Copenhagen Oe, Odense C
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00 - 3. fázisTaking peopleMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Aalborg, Aarhus N, Copenhagen Oe
- Életkor
- 18 év and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00 - 1. fázisFut, nem toborozA Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Odense C, Vejle
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- AbbVie
See details and how to joinNCT05650632 · EU 2023-504674-38-00 - 3. fázisTaking peopleCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Where
- Aarhus N, Copenhagen Oe, Roskilde, Vejle
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00 - 3. fázisFut, nem toborozA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Aalborg, Herning, Næstved, Vejle
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Aarhus N, Copenhagen Oe, Odense C, Roskilde
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisBefejeződöttA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Aarhus N, Copenhagen Oe, Odense C, Vejle
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 3. fázisNot yet taking people in DániaA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Aarhus, København Ø, Odense
- Életkor
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637 - 1. fázisFut, nem toborozA Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Copenhagen Oe
- Életkor
- 18 év and over
- People
- 186 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00 - 3. fázisNot yet taking people in DániaSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Copenhagen, Roskilde, Vejle
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - 3. fázisNot yet taking people in DániaA trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
- Where
- Aarhus N, Copenhagen Oe, Odense C
- Életkor
- 18 év and over
- People
- 249 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-525367-40-00 - 2. fázisNot yet taking people in DániaRestrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
- Where
- Roskilde
- Életkor
- 18 év and over
- People
- 150
- Run by
- Zealand University Hospital
See details and how to joinNCT07842198 - 3. fázisNot yet taking people in DániaA trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
- Where
- Aarhus N
- Életkor
- 18 év and over
- People
- 234 worldwide
- Run by
- AstraZeneca AB
See details and how to join2025-524014-29-00 - 3. fázisNot yet taking people in DániaStudy of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Where
- Århus N
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07764978 - No phaseTaking peopleCompassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
- Where
- Aalborg, Aarhus, Esbjerg, Herning, Odense, Roskilde, Vejle
- Életkor
- 18 év and over
- People
- 920
- Run by
- Christoffer Johansen
See details and how to joinNCT05444348 - 2. fázisTaking peopleTeclistamab in Combination With Pomalidomide Administered in Alternative Fashion in Participants With Relapsed or Refractory Multiple Myeloma.
- Where
- Aarhus N, Odense C
- Életkor
- 18 év and over
- People
- 50 worldwide
- Run by
- Odense University Hospital
See details and how to joinNCT07757412 · EU 2025-522114-23-00 - 1. fázisTaking peopleA Study in Leukemia Patients With Karonudib
- Where
- Aarhus, Copenhagen
- Életkor
- 18 év to 75 év
- People
- 50 worldwide
- Run by
- Thomas Helleday Foundation
See details and how to joinNCT04077307 - 3. fázisTaking peopleA Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Where
- Aarhus N, Roskilde
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- European Myeloma Network B.V.
See details and how to joinNCT06932562 · EU 2024-519827-16-00 - 4. fázisNot yet taking people in DániaBLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
- Where
- Aalborg, Aarhus, Copenhagen, Odense, Roskilde
- Életkor
- 18 év and over
- People
- 400
- Run by
- Anne Louise Tølbøll Sørensen
See details and how to joinNCT07474961 · EU 2026-525658-13-00 - 2. fázisTaking peopleSelf-administration of Subcutaneous Elranatamab in the Patients' Homes.
- Where
- Odense C, Vejle
- Életkor
- 18 év and over
- People
- 20
- Run by
- Thomas Lund
See details and how to joinNCT06015542 · EU 2023-507876-30-00 - No phaseTaking peopleExamination of Vertebroplasty in Addition to Regular Treatment of Patients With Multiple Myeloma.
- Where
- Middelfart
- Életkor
- 18 év and over
- People
- 90
- Run by
- Spine Centre of Southern Denmark
See details and how to joinNCT04533217 - 2. fázisNot yet taking people in DániaBispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Where
- Copenhagen, Odense, Vejle
- Életkor
- 18 év to 70 év
- People
- 50 worldwide
- Run by
- North Estonia Medical Centre
See details and how to joinNCT06505369